Mark D. Ewalt, MD
Program Director, Molecular Genetic Pathology Fellowship
Hematopathology; Molecular Pathology
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Contact and Location
- Speaks English
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.See all locations
MD, Columbia University College of Physicians and Surgeons
Anatomic and Clinical Pathology – NewYork-Presbyterian Hospital/Columbia University Medical Center
Hematopathology - Stanford Healthcare; Molecular Genetic Pathology - Stanford Healthcare
Anatomic and Clinical Pathology; Hematology (Pathology); Molecular Genetic Pathology
I am a pathologist who specializes in molecular genetic pathology and hematopathology. I also have an interest in developing new genetic tests for leukemia and lymphoma.
My molecular pathology work involves looking at mutations in samples from patients with cancer to diagnose, monitor, and help guide their therapies. This information also helps ensure each patient’s treatment plan is personalized to their unique cancer. As part of the Hematopathology Service, I integrate clinical and genetic information with microscopic and flow cytometry evaluation of patient tissues to diagnose blood cancers such as leukemia and lymphoma.
My research is focused on identifying the genetic changes that drive leukemia and lymphoma to uncover prognostic and therapeutic markers. This work dovetails with my clinical test development role in the Diagnostic Molecular Pathology Service.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Hematopathology doctors
See all Molecular Diagnostics doctors
See all Diagnostic Molecular Pathology Service doctors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.Search clinical trials
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Mark D. Ewalt discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].